BRIEF published on 11/26/2025 at 00:51, 3 months 5 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 3 months 5 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 3 months 6 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 3 months 6 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 6 months 16 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 6 months 16 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 6 months 24 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 6 months 24 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 8 months 6 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 8 months 6 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 02/28/2026 at 10:00, 1 day 2 hours ago Storm Exploration Issues Shares to Eabametoong First Nation
Published on 02/28/2026 at 00:10, 1 day 12 hours ago Algo Grande Copper Closes Oversubscribed $6.52 Million Financing and Strengthens Board at AGM
Published on 03/01/2026 at 11:05, 1 hour 47 minutes ago Acwa Board of Directors names Dr. Samir J. Serhan Chief Executive Officer
Published on 03/01/2026 at 10:30, 2 hours 23 minutes ago Huawei Launches Comprehensive U6GHz Portfolio to Unlock 5G-A Potential and Pave the Way for 6G
Published on 02/28/2026 at 21:50, 15 hours 2 minutes ago CARLSBERG MAKES EVERY FAN FEEL PART OF MATCHDAY WITH BSL RENDITION OF "YOU'LL NEVER WALK ALONE"
Published on 02/28/2026 at 21:20, 15 hours 32 minutes ago Huawei's SuperPoD Portfolio Creates New Option for Global Computing at MWC Barcelona 2026
Published on 02/28/2026 at 21:00, 15 hours 52 minutes ago CARLSBERG MAKES EVERY FAN FEEL PART OF MATCHDAY WITH BRITISH SIGN LANGUAGE RENDITION OF 'YOU'LL NEVER WALK ALONE'
Published on 02/27/2026 at 23:00, 1 day 13 hours ago Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Published on 02/27/2026 at 18:02, 1 day 18 hours ago AXA: Execution of a share repurchase agreement in relation to AXAs share buy-back program of up to Euro 1.25 billion
Published on 02/27/2026 at 17:45, 1 day 19 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
Published on 02/27/2026 at 17:45, 1 day 19 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026
Published on 02/27/2026 at 08:45, 2 days 4 hours ago Air Liquide and Holcim sign an agreement to decarbonize cement production with a carbon capture project in Belgium
